A Population Based Study Of Endocrine Hypertension
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 26-004528
About this study
The purpose of this study is to estimate the prevalence of primary aldosteronism, hypercortisolism, primary aldosteronism and/or hypercortisolism among adults with apparent resistant hypertension in the expanded Rochester Epidemiology Project (REP) population, encompassing a 27-county region in southern Minnesota and western Wisconsin. In addition, externally validate and refine an artificial intelligence (AI)–based prediction algorithm for detection of primary aldosteronism in a population-based setting.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
Age ≥18 years
Resident of the expanded Rochester Epidemiology Project (REP) region, defined as the 27-county area in southern Minnesota and western Wisconsin, during the study period
Apparent resistant hypertension, defined as:
systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg while prescribed ≥3 antihypertensive medication classes (ideally including a diuretic), or
controlled blood pressure (<130/80 mmHg) while prescribed ≥4 antihypertensive medication classes
Active care within a REP-participating healthcare system, with sufficient electronic health record data to ascertain blood pressure and antihypertensive medication use
Willingness and ability to provide informed consent
Willingness to undergo study procedures, including blood sampling and overnight dexamethasone suppression testing
Exclusion Criteria:
Known diagnosis of PA already fully established and treated
Known adrenal insufficiency or hypercortisolism
Current oral glucocorticoid therapy
Pregnancy
End-stage illness or inability to safely participate
Inability to comply with required medication or testing instructions
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 04/20/2026. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Irina Bancos, M.D., M.S. |
Contact us for the latest status |
|
More information
Publications
Publications are currently not available